Clinical Trial Detail

NCT ID NCT02193347
Title RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Duke University
Indications

malignant glioma

Therapies

PEPIDH1M vaccine

Age Groups: adult

Additional content available in CKB BOOST